This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
In recent years, the adoption of advanced treatments in inflammatory bowel disease has evolved. Oral products have captured a significant share in ulcerative colitis, while Skyrizi, a 3rd generation biologic, has gained share in Crohn’s Disease. Despite these newer entrants, 1st generation biologics maintain significant patient share in both diseases.
This article, co-authored by CRA’s Will Foster and Juliette Richards, explores how advances in artificial intelligence (AI), data collection, and connected...
Direct-to-consumer (DTC) and cash-pay models are not simply creating another access route, they are beginning to influence payer strategy, employer benefit...
